Teens with attention-deficit/hyperactivity disorder (ADHD) - the most common childhood psychiatric condition in the United States - are less likely to finish high school on time than students with other mental-health disorders that often are considered more serious, a large national study by researchers at the UC Davis School of Medicine has found...
6 Vote(s)
July 29, 2010
January 26, 2010
How to measure attention span of a fly: Implications for ADHD, autism in humans
An Australian-German team of scientists has found a way to measure the attention span of a fly. The findings could lead to further advances in the understanding of attention-deficit hyperactivity disorder (ADHD) and autism in humans.
16 Vote(s)
16 Vote(s)
Comments Off
January 13, 2010
Cardiac Risk of Stimulants for Children With ADHD:
New guidelines to assess cardiac risk before using stimulant medication in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) were published concurrently in 3 Canadian medical society journals in November. Publication of these guidelines coincided with an FDA announcement of a delay in a US epidemiological study of the potential cardiovascular risk.
7 Vote(s)
7 Vote(s)
Comments Off
January 8, 2010
New Treatment For Hyperactivity In Children
A new thought-operated computer system which can reduce the symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in children will be rolled out across the UK this month...
5 Vote(s)
5 Vote(s)
Comments Off
New treatment for hyperactivity in children: Thought-operated computer system
A new thought-operated computer system which can reduce the symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in children is being be rolled out across the UK.
16 Vote(s)
16 Vote(s)
Comments Off
November 14, 2009
Shire Reports Analysis Examining Emotional Lability In Children With ADHD Taking Vyvanse
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Sc
9 Vote(s)
9 Vote(s)
Comments Off
September 15, 2009
Alterations In Brain Dopamine Pathway Appears To Be Associated With Certain Symptoms Of ADHD
Results from brain scans suggest an association between a reduction in the transmission of dopamine markers with symptoms of inattention for individuals with attention deficit/hyperactivity disorder (ADHD), according to a preliminary study in the September 9 issue of JAMA. ADHD is a childhood psychiatric disorder that frequently persists into adulthood, and is estimated to affect 3 percent t
9 Vote(s)
9 Vote(s)
Comments Off
August 2, 2009
Study Demonstrated Once-Daily Vyvanse(R) CII Provided Significant Improvement Of ADHD Symptoms For Children At 13 Hours After Administration
Shire plc announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last time point assessed (13 hours) afte
10 Vote(s)
10 Vote(s)
Comments Off
July 17, 2009
Children With Fetal Alcohol Spectrum Disorders (FASD) Have More Severe Behavioral Problems Than Children With Attention Deficit Hyperactivity Disorder (ADHD), Study Finds
Children with fetal alcohol spectrum disorders (FASD) have a high risk of psychiatric problems, including attention deficit hyperactivity disorder (ADHD). Children with FASD are often initially diagnosed with ADHD. A first-of-its-kind study shows that children with FASD have a distinct behavioural profile: significantly weaker social cognition and facial emotion-processing abilities than children
8 Vote(s)
8 Vote(s)
Comments Off
July 3, 2009
VYVANSE CII Provided Significant Efficacy At 14 Hours After Administration In Adults With ADHD In An Adult Simulated Workplace Environment
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results from a Phase 3b study that found VYVANSE® (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD).
7 Vote(s)
7 Vote(s)
Comments Off